Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
BACKGROUND
New molecular profiling technologies can aid in analysis of small pathologic samples obtained by minimally invasive biopsy and may enable the discovery of key biomarkers synergistic with anatomopathologic analysis related to prognosis, therapeutic response, and innovative target validation. Thus proteomic analysis at the histologic level in healthy and pathologic settings is a major issue in the field of clinical proteomics.


METHODS
We used surface-enhanced laser desorption ionization-time-of-flight mass spectrometry (SELDI-TOF MS) technology with surface chromatographic subproteome enrichment and preservation of the spatial distribution of proteomic patterns to detect discrete modifications of protein expression. We performed in situ proteomic profiling of mouse tissue and samples of human cancer tissue, including brain and lung cancer.


RESULTS
This approach permitted the discrimination of glioblastomas from oligodendrogliomas and led to the identification of 3 potential markers.


CONCLUSIONS
Direct tissue proteomic analysis is an original application of SELDI-TOF MS technology that can expand the use of clinical proteomics as a complement to the anatomopathological diagnosis.
Bouamrani
Ali
A
INSERM U318, Université de Grenoble, Department of Neurosurgery, Centre Hospitalier Universitaire Grenoble, France.
Ternier
Jessica
J
Ratel
David
D
Benabid
Alim-Louis
AL
Issartel
Jean-Paul
JP
Brambilla
Elisabeth
E
Berger
François
F
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D016543:Central Nervous System Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D005909:Glioblastoma / Q000737:chemistry* / Q000175:diagnosis; D006801:Humans; D051379:Mice; D009837:Oligodendroglioma / Q000737:chemistry* / Q000175:diagnosis; D009928:Organ Specificity; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*
D015415:Biomarkers